- This event has passed.
Twitter Chat: Emergency Medicine Management of Severe Alcohol Withdrawal
October 20 @ 2:00 pm - 3:00 pm
Join us on Twitter @TreatmentWeek on Tuesday, October 20th as Lewis Nelson, MD shares his expertise on alcohol withdrawal management in the hospital setting.
Lorenzo Leggio, M.D., Ph.D.
Dr. Lorenzo Leggio is a Senior Investigator (Clinical) at the National Institutes of Health Intramural Research Program (NIH IRP) and serves as the Chief of the Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, a joint NIDA and NIAAA laboratory, and is the upcoming Chief of the new NIDA IRP Translational Addiction Medicine Branch. Dr. Leggio received his M.D. and Ph.D. from the Catholic University of Rome and ‘Agostino Gemelli’ hospital, where he also completed residency and received Board Certification in Internal Medicine. He also received a Masters in ‘Alcohol-related diseases and problems’ from the University of Florence. He was a visiting research associate, then postdoctoral research associate in Psychiatry and Human Behavior at Brown University, Providence, RI. In 2010, Dr. Leggio joined the faculty of the Brown University Medical School as Assistant Professor and Core Faculty at the Brown University Center for Alcohol and Addiction Studies (CAAS). Dr. Leggio’s clinical research has been primarily focused on the treatment of alcohol and substance use disorders, with a special emphasis on the role of neuroendocrine as well as GABAergic pathways; and on the medical consequences of alcohol use disorder, with a special emphasis on alcohol-associated liver disease. As a Principal Investigator at Brown University, Dr. Leggio received extramural research funding from NIAAA and NIDA, as well as from the European Foundation for Alcohol Research, Brown University CAAS, ABMRF/The Foundation for Alcohol Research, and the Brain & Behavior Research Foundation (formerly NARSAD). In 2012, Dr. Leggio joined the NIAAA and NIDA Intramural Research Programs (IRPs) as a joint Tenure-Track Clinical Investigator. He was awarded NIH tenure through the Central Tenure Committee and promoted to Senior Investigator (Clinical) in 2018 – two years early before his tenure-track clinical appointment was completed. Dr. Leggio also serves as Senior Medical Advisor to the NIAAA Director, a NIH Senior Attending Medical Staff, the Associate Director for Clinical Research for the NIDA IRP Medication Development Program and Faculty Member of the NIH Center on Compulsive Behaviors. Additionally, he is a Professor (Adjunct) at Brown University, Johns Hopkins University and Georgetown University. Dr. Leggio’s lab has pioneered clinical research on the role of neuroendocrine signaling in alcohol- and drug-seeking behaviors via preclinical and human laboratory studies. He has authored or co-authored over 170 peer-reviewed manuscripts and has served as a regular reviewer for many journals, reviewer for NIH study sections and other U.S. and international funding agencies and member of an FDA Advisory Board. He currently serves on the editorial board of several addiction-related journals and is a member of the Advisory Council of the Peter G. Dodge Foundation. Dr. Leggio has served as Chair (Medical/Clinical) of the 2016 Research Society on Alcoholism (RSA) Program Committee, is a member of the American College of Neuropsychopharmacology (ACNP) and is also Founder and Chair of the Psychoneuroendocrinology Scientific Interest Group within the NIH IRP. Among other awards, he received the 2008 European Society for Biomedical Research on Alcoholism (ESBRA) Nordmann Award, the 2015 NIAAA Clinical Service Award, the 2016 NIAAA Mentoring Award, the 2016 RSA Early Career Investigator Award and the 2018 NIAAA Scientific Achievement Award. In 2018, Dr. Leggio was presented with the ACNP Eva King Killam Award on the basis of outstanding translational research contributions to neuropsychopharmacology.
Falk Lohoff, M.D.
Dr. Falk Lohoff serves as the Chief of the Section on Clinical Genomics and Experimental Therapeutics (CGET). He received his medical degree from Humboldt University of Berlin in 2002, and completed residency training in psychiatry and a fellowship in neuropsychopharmacology at the University of Pennsylvania. He is board certified in Psychiatry since 2007. He was Assistant Professor of Psychiatry at the University of Pennsylvania from 2007-2014, after which he joined the NIH intramural program as a Lasker Clinical Research Scholar. Dr. Lohoff has worked on clinical trials in mood and anxiety disorders and has also been involved in direct patient care as the attending at the University of Pennsylvania. His research is focused on translational medicine and spans areas of molecular genetics, epigenetics, imaging-genetics, pharmacogenetics and clinical experimental trials.